abrdn Healthcare Investors

abrdn Healthcare Investors

Abrdn Healthcare Investors was formed as one of several specialized closed-end funds managed by UK-headquartered abrdn plc. The fund invests primarily in equity securities of US and non-US healthcare companies, a mandate it has maintained since its launch. Its manager, abrdn Inc., is the North American asset management subsidiary of the parent group, which directs the portfolio's exposure to drug developers, device makers, insurers, and care providers. The fund's strategy concentrates long investments across the healthcare ecosystem, from large-cap pharmaceutical and biotech franchises to mid- and small-cap firms with higher growth trajectories. Positions span pharmaceuticals, biotechnology, medical devices, healthcare equipment, life-sciences tools, and managed care organizations. It may also invest up to 20% of assets in healthcare-related debt. The fund occasionally employs option-writing strategies to generate additional income, and it can use leverage through bank facilities to increase investment exposure. The geographic mix skews heavily toward US-listed securities but includes exposure to European and Asian markets (per the fund's regulatory filings, 2024). The fund is externally managed by abrdn Inc. and its board of trustees oversees governance, with day-to-day portfolio management carried out by abrdn's dedicated healthcare equity team. Its shares are publicly traded, and the vehicle maintains an at-the-market offering program for additional issuance. The fund historically distributed managed payments tied to a stated distribution policy, at times returning capital alongside income and gains. In July 2024, abrdn plc announced executive leadership changes, including the appointment of a new group CEO, while the US-listed closed-end funds continued to operate under their existing portfolio management teams. The closed-end structure itself differentiates the fund from open-end peers: it trades throughout the day on an exchange with a price set by market demand, often at a premium or discount to net asset value. This structure allows the managers to deploy leverage and hold less-liquid positions without facing redemption pressures, creating a permanent capital base tailored for long-term, conviction-weighted healthcare investing.